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The 13kDa heparin-binding growth factor midkine (MK) was originally identiﬁed as a molecule
involved in the orchestration of embryonic development. Recent studies provided evidence for a
new role of MK in acute and chronic inﬂammatory processes. Accordingly, several inﬂammatory
diseases including nephritis, arthritis, atherosclerosis, colitis, and autoimmune encephalitis have
been shown to be alleviated in the absence of MK in animal models. Reduced leukocyte
recruitment to the sites of inﬂammation was found to be one important mechanism attenuating
chronic inﬂammation when MK was absent. Furthermore, MK was found to modulate expression
of proinﬂammatory cytokines and the expansion of regulatory T-cells. Here, we review the current
understanding of the role of MK in different inﬂammatory disorders and summarize the knowledge
of MK biology.
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1. INTRODUCTION
The cytokine midkine (MK) was ﬁrst discovered in the eighties of the last century as a molecule involved
in embryonic development [1]. MK was found to be rarely expressed in the adult organism, but different
types of cancer cells showed high MK expression associated with a poor prognosis of the patients [2–
6]. Several studies revealed that overexpression of MK promoted tumor growth, survival, invasion, and
tumor angiogenesis [7–9]. However, there is growing evidence that MK may also play an important role in
chronic inﬂammatory disorders including, for example, kidney diseases, rheumatoid arthritis, inﬂammatory
bowel disease, and multiple sclerosis as summarized in Table 1 [10–13]. The fact that these diseases exhibit
high clinical and epidemiological relevance and affect the patients’ quality of life dramatically makes it
worthwhile to take a deeper look at a new factor possibly contributing to the induction and/or maintenance
of these pathological conditions. In this paper, we summarize the ﬁndings on the role of MK in chronic
inﬂammatory diseases and give an overview of MK biology including its gene and protein structure as well
as its receptors and signaling.
2. GENE AND PROTEIN
MK was ﬁrst identiﬁed in mouse embryonic carcinoma cells in studies on early stages of embryogenesis.
In this model, differentiation of embryonic carcinoma cells by application of retinoic acid, one of the
key players coordinating embryogenesis, led to increased MK mRNA expression in these cells [1]. In
mouse embryos, MK was found to be induced at day 7 and showed a complex expression pattern at
day 11 when organogenesis had started. After the midgestation stage, MK expression rapidly decreased
and was thereafter only detectable at restricted sites such as the kidney. In situ hybridization technique
in mouse embryos between days 7 and 13 revealed strong MK expression in epithelial tissues interacting
with mesenchymal tissues during organ formation, in neuronal tissues, in the mesoderm where remodeling
occurred, in the anterior lobe of the pituitary gland, in the retina, and in the kidney. This mode of expression
considering gestation in mice lasting about 21 days was one of the reasons to give this molecule the name
midkine (midgestation, kidney) [14].
While the human MK gene (MDK) is located on chromosome 11, the mouse MK gene was identiﬁed
on chromosome 2 [15, 16]. The coding sequence of the human and mouse MK gene consists of 4 exons.
In the promoter region of the MK gene, a retinoic acid response element (RARE), a hypoxia-responsive
element (HRE), and a binding site for the product of the Wilms tumor suppressor gene WT-1 leading to
decreased MK expression upon WT-1 binding were found [17–19].
As shown by NMR technique, the human 13kDa protein MK consists of two similar domains each
containing three antiparallel β-strands which are connected via disulﬁde bonds (Figures 1(a) and 1(b))
[20, 21]. MK is rich in basic amino acids forming two clusters responsible for heparin binding which are
located in the C-terminal domain, namely, cluster 1 (K79, R81, and K102 in human MK) and cluster 2 (K86,
K87, R89 in human MK). Although the N-terminal domain also contains several basic residues, the heparin-
binding activity is very weak which is probably due to the existence of several acidic amino acids in this
domain [20]. The C-terminal domain has been found to be functionally more important than the N-terminal
domain [22]. Accordingly, different MK functions, for example, the promotion of neurite outgrowth or
plasminogen activator activity are mediated by the C-terminal domain [23–25]. However, only the full
length molecule, not the C-terminal domain by itself, was able to promote survival of embryonic brain
neurons [23]. For some of its functions as, for example, enhancement of plasminogen activator activity, MK
needs to dimerize which is mediated by a head-to-head conformation involving heparin being sandwiched
by the cluster 2 heparin binding sites of two MK molecules [20, 26]. Transglutaminase activity and heparin
have been found to be capable of promoting MK dimerization [26, 27].
MK represents the founding member of a family of heparin-binding growth factors and is structurally
unrelated to any other growth factor family known so far consisting of only one other member named
pleiotrophin (PTN). MK and PTN are highly conserved within the different species. While human MK
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TABLE 1: Overview of the role of MK in chronic inﬂammatory diseases.
Organ Disease Model/specimen Publication
Kidney
Diabetic nephropathy
Streptozotocin-induced diabetic
nephropathy
Kosugi et al. 2006 [28],
Kosugi et al. 2007 [10]
Tubulointerstitial injury Ischemia/reperfusion
Sato et al. 2001 [29],
Sato et al. 2005 [30]
Drug side effects Cisplatin-induced renal damage Kawai et al. 2004 [31]
Joints
Rheumatoid arthritis
Human synovial ﬂuid, human
synovial tissue
Takada et al. 1997 [32]
Antitype II collagen
antibody-induced arthritis
Maruyama et al. 2004 [11]
Vascular System Atherosclerosis
Intimal hyperplasia in vein grafts Banno et al. 2006 [33]
In-stent restenosis Narita et al. 2008 [34]
Neointima formation in restenosis Horiba et al. 2000 [35]
Colon
Crohn’s disease Human blood
Krzystek-Korpacka et al.
2010 [12]
Ulcerative colitis
Dextran-sulfate-sodium- (DSS-)
induced colitis
Yuki et al. 2006 [36]
Central nervous
system
Multiple sclerosis
Experimental autoimmune
encephalomyelitis (EAE)
Liu et al. 1998 [37],
Wang et al. 2008 [13]
shares 87% sequence identity with mouse MK, human MK and PTN have about 50% sequence identity
(Figure 2(a))[ 38–40]. All cysteine residues in both molecules are conserved in the human and murine
system [21]. The basic amino acids that form the clusters for heparin-binding are also highly conserved
in MK and PTN (Figure 2(b)). As an exception, the basic amino acid K84 in human MK is changed to
R 8 4i nh u m a nP T N[ 22]. Although MK and PTN share distinctive sequence similarities, both proteins
show different expression patterns. While MK is highly expressed during midgestation as mentioned above,
the expression peak of PTN in mice occurs around birth [41]. In Drosophila melanogaster, two MK/PTN
homologues have been identiﬁed, named miple1 and miple2 (midkine, pleiotrophin) [42]. The amino acid
sequence of miple1 and miple2 is about 60% identical to human MK and human PTN with particularly high
homology to the C-terminal domain. The basic amino acids in the heparin-binding clusters are partially
conserved in the miple proteins [42].
3. RECEPTORS AND SIGNALING
MK binds a variety of different receptors and an overview of these receptors is shown in Table 2.M Kh a s
been found to promote, for example, growth, survival, migration, and gene expression of different cell types
probably via a multiprotein receptor complex consisting of several molecules [43]. Within this complex,
the best characterized receptor represents the receptor-like protein tyrosine phosphatase β/protein tyrosine
phosphatase ζ (PTPζ), which is abundantly expressed in the central nervous system mediating cell adhesion
and signaling during embryonic development [44]. PTPζ is a transmembrane protein with intracellular
tyrosine phosphatase activity linked to an extracellular chondroitin sulfate chain [45]. The fact that the
binding afﬁnity of MK to PTPζ decreased from a Kd of 0.56nM to 8.8nM after removal of the chondroitin
sulfate chain indicated its importance for ligand-receptor recognition [45]. Binding of MK to PTPζ induced
migration of embryonic neurons as well as UMR106 osteoblast-like cells and enhanced survival of neurons
during embryonic development [45–47]. Inhibition of different kinases such as PI3 kinase, MAP kinases,
Src family kinases, and protein kinase C impaired MK-dependent migration of UMR-106 cells implying
the involvement of multiple kinases in downstream signaling upon MK binding to PTPζ [46].
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FIGURE 1: Protein structure of MK. (a) MK protein structure is shown. MK consists of two domains with
similar size connected by an interdomain (white box). Numbers indicate amino acid position within the
protein. The heparin-binding sites consisting of basic amino acids are located in the C-terminal domain
(green boxes) [20]. (b) Tertiary structure of the C-terminal domain of MK protein “taken from the protein
data bank PDB via http://www.rcsb.org/pdb/explore.do?structureId=1MKC.” The C-terminal domain contains
three β-strands (yellow structure). Heparin binding clusters consisting of basic amino acids (cluster 1: K79,
R81, K102; cluster 2: K86, K87, R89 in human MK) are displayed as green dots. C62, C72, C94, and C104
represent highly conserved cysteine residues forming disulﬁde bonds (black lines) [20].
In addition to PTPζ, members of the low-density-lipoprotein receptor-related protein (LRP) family
have been identiﬁed as components of the MK receptor complex including LRP-1, megalin/brushin, LRP-6,
and apoE receptor-2 [47, 48]. LRP-1 induced survival of embryonic neurons and prevented hypoxic injury
in mouse embryonic stem cells upon MK binding with a Kd of 3.5nM, whereas binding afﬁnity of MK to
the other LRP family members mentioned above was signiﬁcantly lower [47–49].
In 13-day-old mouse embryos, β1 integrins were identiﬁed as functional MK receptors. MK binding
to α4β1-integrin mediated migration of UMR-106 osteoblast-like cells [51]. In these cells, MK treatment
led to increased tyrosine phosphorylation of paxillin which interacts with the cytoplasmatic tail of β
integrins [52, 61]. Via α6β1-integrin binding, MK induced neurite outgrowth of embryonic neurons [51].
Furthermore, MK promoted the association of the α6β1-integrin and the tetraspanin CD9, which belongs to
a family of highly conservedreceptor proteins forming multimeric complexeswith other membrane proteins
and thereby modulating cell adhesion, proliferation, and metastasis [52, 62]. The fact that α4β1and α6β1
integrins coimmunoprecipitated with the LRP-6 ectodomain and PTPζ upon MK treatment suggested a
functional interaction of these molecules in an MK receptor complex [51].
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FIGURE 2: Sequence homologies of MK and PTN. (a) Amino acid sequence of human MK and murine MK
as well as human MK and human PTN. Human and murine MK show 87% amino acid sequence identity;
human MK and PTN share 50% sequence homology.   = residues identical in both sequences [38–40]. (b)
Web logos displaying sequence homology of human MK, murine MK, chicken MK, miple1, and human PTN
in information bits [50]. A large overall height indicates strong conservation of the corresponding amino acid
in that position; the height within the stack shows the relative frequency of the amino acid at that position.
Cysteine residues (black circle) and basic amino acids (green circle) are highly conserved within different
species of the MK family.
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Recently, neuroglycan C was found to serve as an MK receptor in an oligodendrocyte precursor-
like cell line [54]. Neuroglycan C is a chondroitin sulfate proteoglycan exclusively expressed in the central
nervous system contributing to brain development [63]. Similar to PTPζ, the binding afﬁnity of neuroglycan
C to MK was impaired when chondroitin sulfate chains were absent [54]. In addition, MK binds to Notch2,
a transmembrane protein belonging to the Notch family. Here, MK was found to be involved in induction
of epithelial mesenchymal transition (EMT) of immortalized HaCaT keratinocytes indicated by a decrease
of epithelial and an increase of ﬁbroblast markers [64]. EMT is a process that occurs during embryonic
development as well as in tumor metastasis and is characterized by loss of cell contacts in order to allow
cell migration [64]. An interaction between MK and Notch2 promoting EMT was also shown in pancreatic
ductal adenocarcinoma cells (PDACs) [53]. Furthermore, Notch2 signaling upon MK binding upregulated
NFκB implying an involvement of MK in inﬂammatory pathways [53]. Moreover, anaplastic lymphoma
kinase (ALK), a transmembrane tyrosine kinase mediating survival, proliferation, and differentiation of
normal and tumor cells wasidentiﬁed asMK receptor[7,65]. MK promoted colonyformation of the adrenal
gland SW-13 tumor cell line in soft agar and induced proliferation of human endothelial cells via ALK
signaling [7]. In WI-38 human ﬁbroblasts, MK stimulation led to phosphorylation of ALK and subsequent
activation of PI3 kinase and MAP kinase [7].
The fact that most MK effects were diminished upon administration of heparin or treatment with
heparitinase or chondroitinase indicated the importance of carbohydrate recognition in MK signaling. Two
speciﬁc carbohydrate structures, namely, heparan sulfate trisulfated units or chondroitin sulfate E units—
when present as oligomers—have been shown to bind to MK with high afﬁnity [55–57]. As mentioned
above, chondroitin sulfate chains linked to PTPζ enhanced MK binding afﬁnity. Syndecans and glypican-
2, carbohydrates involved in the neuronal development, also showed MK binding activity contributing to
development of the central nervous system, neuronal cell migration, and neurite outgrowth [58–60].
In conclusion, MK represents a promiscuous ligand that binds different receptors thereby activating
several intracellular signaling events. However, the intracellular signal transduction pathways that mediate
t h ee f f e c t so fM Ki ni n ﬂammation are widely unknown.
4. MK AS A MODULATOR OF THE INFLAMMATORY RESPONSE
4.1. Kidney
There is a growing body of evidence that MK plays a critical role during inﬂammation. In the adult
organism, MK shows constitutive expression in proximal renal tubular epithelial cells, and different
pathologicalkidneyconditionsincludingdiabeticnephropathyhavebeenlinkedtoenhancedMKexpression
[10, 29–31]. Diabetic nephropathy caused by diabetes mellitus represents the main cause of end-stage renal
failure and dialysis requirement accompanied by high mortality and exceeding cost of care [66]. During
diabetic nephropathy which is associated with tubulointerstitial inﬂammation, glomeruli, interstitium, and
tubules of patients showed highly increased MK expression in contrast to healthy patients [10]. In a
diabetes mouse model where hyperglycemia was induced by application of streptozotocin which impairs
insulin production by selective destruction of β-cells of the pancreas and results in elevated glucose
levels, tubulointerstitial damage was less severe in mice lacking MK expression compared to WT control
animals within 2 to 6 months after the onset of the experiment. This suggests that MK may aggravate the
inﬂammatory response in diabetic nephropathy [10, 28].
Inﬂammation induced by ischemia/reperfusion (I/R) in the kidney, which is one of the main causes
of acute renal failure in humans, led to increased MK expression in the renal tubules two days after ligation
of renal arteries for 90 minutes in a mouse model. Seven days after I/R, MK expression returned to baseline
values [29, 30]. In MK-deﬁcient mice or mice treated with MK antisense oligodeoxyribonucleotides,
tubulointerstitial damage was reduced compared to control conditions [29, 30]. Furthermore, renal damage
caused by cisplatin—a chemotherapeutic drug used for the treatment of different kinds of cancer—was
found to be reduced in MK-deﬁcient mice implying that MK may exacerbate side effects of drugs in the
2497TheScientiﬁcWorldJOURNAL (2011) 11, 2491–2505
kidney [31]. However, in all pathological conditions mentioned above, reduced renal damage in the absence
of MK was associated with impaired inﬁltration of inﬂammatory cells into the renal tissue [10, 29–31].
This is in line with the ﬁnding that monocyte chemotactic protein 1 (MCP-1, CCL2) and macrophage
inﬂammatory protein (MIP-2, CXCL2) were upregulated in WT mice upon I/R of the kidney. Similarly,
MCP-1 expression was found to be increased in streptozotocin-induced diabetic nephropathy [10, 29, 30].
Thus, MK may be able to contribute to the recruitment of leukocytes by induction of chemokine expression
in the kidney. Both chemokines are known to mediate leukocyte inﬁltration and upregulation of these
proteins was diminished in mice lacking MK expression [10, 29]. Studies with cultured tubular epithelial
cells(TEC)revealedthathighglucoselevelsmimickingthediabetesmodelandH2O2 mimickingconditions
during ischemia induced MK expression in TEC and increased MCP-1 and MIP-1 expression in these cells.
This effect was not observed in cells of MK-deﬁcient mice or in cells treated with an MK blocking antibody
[10,29].Inaddition,recombinantMKenhancedMCP-1andMIP-1expressioninTEC[29].Thus,induction
of chemokines by MK may at least partially explain the reduced recruitment of inﬂammatory cells into the
kidney under inﬂammatory conditions in the absence of MK. In addition, MK by itself has been reported to
act as a haptotactic and chemotactic agent for neutrophils in a Boyden chamber [32]. However, leukocyte
inﬁltration was diminished during Cisplatin-induced renal inﬂammation in the genetic absence of MK or
upon downregulation of MK by antisense technique, whereas no difference in expression pattern of MCP-1
was observed [31]. Thus, the induction of chemokines may represent not the only mechanism mediating
leukocyte recruitment in the kidney. Taken together, MK may aggravate different pathologies of the kidney
by enhanced recruitment of leukocytes. The question whether MK is able to induce additional inﬂammatory
chemokines besides MCP-1 and MIP-2 and how MK exactly contributes to leukocyte trafﬁcking still needs
to be investigated.
4.2. Joints
Rheumatoid arthritis (RA), an autoimmune disease leading to chronic joint inﬂammation, subsequent joint
destruction, and deformities, is of high clinical and epidemiological relevance affecting approximately
from 0.5% to 1% of the adults worldwide with a higher prevalence in women [67]. High levels of RF—
autoantibodies against the Fc fragment of IgG—can be detected in 80% of RA patients and correlate
with the susceptibility to developing RA and severe joint damage. However, RF is also elevated in other
autoimmune diseases and does not correlate with disease activity [68]. Of note, synovial ﬂuid and sera of
90% of patients suffering from RA showed enhanced MK levels. MK levels correlated positively with RF
[11]. Inﬂamed tissues of patients with active inﬂammatory synovitis of RA expressed high concentrations of
MK, whereas noninﬂamed tissue showed no MK expression at all [32]. Elevated MK expression in a large
numberofRApatientsindicatedthatMKmayrepresentanewadditionalbiomarkerforthediagnosisofRA.
Furthermore, the functional relevance of MK during arthritis was investigated in a murine arthritis model
where joint inﬂammation was induced by injection of an antitype II collagen Ab followed by intra-articular
LPS administration [69]. While control mice developed severe arthritis until day 7 measured by joint cavity
size, synovial membrane thickening, and accumulation of synovial ﬂuid, the inﬂammatory response was
almost completely absent in MK-deﬁcient mice. However, intraperitoneal administration of recombinant
MK restored this effect and led to severe arthritis in this model. As seen in the kidney, the number of
extravasated neutrophils and macrophages into the synovial tissue in MK-deﬁcient mice was decreased
after 2 to 7 days when compared to WT control animals at the same time point indicating that MK may
represent a critical player for pathogenesis of RA [11].
4.3. Vascular System
Although risk factors for development and maintenance of atherosclerosis including hypercholesterolemia,
free radicals from cigarette smoking, diabetes mellitus, and hypertension have been clearly identiﬁed,
cardiovascular diseases still represent the main cause of death in Europe and in the United States.
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Atherosclerosis is a chronic inﬂammatory disease of large- and medium-sized arteries characterized by
endothelial dysfunction and subsequent plaque formation of the vascular wall. Under healthy conditions,
arteries and veins express MK at a very low level [34]. However, injury of the endothelium caused
by experimental interventions led to increased MK expression in different rabbit and mouse models
[33, 35]. Macrophages inﬁltrating the injured vascular wall after stenting have been found to be a
major source of MK, whereas freshly isolated monocytes did not express MK [34]. Clinically, mechanic
vessel injury is followed by an inﬂammatory response causing neointima formation which may lead to
restenosis after therapeutic intervention. Leukocytes play an important role in this context by secreting
factors which promote migration and proliferation of smooth muscle cells (SMCs) and maintain an
inﬂammatory environment [70]. Compared to control mice, neointima formation was almost completely
absent in MK-deﬁcient mice [35]. This was in line with the ﬁnding that leukocyte recruitment to the
injured vessel wall was reduced in MK-deﬁcient mice compared to control animals. However, intra-arterial
administration of recombinant MK restored neointima formation [35]. Endothelial cells of implanted vein
grafts interpositioned into an artery in rabbits also strongly expressed MK. When grafts were treated with
MK siRNA, intima thickness and leukocyte inﬁltration into the vessel wall was signiﬁcantly reduced
suggesting that MK promoted leukocyte inﬁltration into the vascular wall after intervention-associated
vessel injury [33].
4.4. Colon
Approximately 1.4 million people in Europe are diagnosed—generally in late adolescence or early
adulthood—with inﬂammatory bowel disease (IBD) which consists of two major forms, namely, ulcerative
colitis (UC) and Crohn’s disease (CD) [71]. Both pathologic entities are characterized by autoimmune-
mediated inﬂammation of the gastrointestinal tract. In CD, MK serum levels showed positive correlation
with Crohn’s Disease Activity Index (CDAI) which includes vital parameters, clinical ﬁndings, and
medical history [12, 72]. Accordingly, MK has been found to be a sensitive biomarker of diagnostic value
comparable with the gold standard C-reactive protein (CRP) in this disease [12]. In an experimental colitis
model, where bowel inﬂammation was induced by dextran sulfate sodium (DSS) and which represents a
well-established model for UC, MK was abundantly expressed in ﬁbroblasts of the mucosal and submucosal
layers of the rat distal colon [36]. Here, TNF-α and IL-1β, which show high local expression during active
IBD in humans leading to inﬁltration of innate immune cells, were expressed in the distal rat colon [36, 73].
In addition, both cytokines induced MK expression in the rat ﬁbroblast cell line 3Y1. Moreover, MK was
found to accelerate intestinal wound repair in vitro using cultured epithelial monolayer sheets suggesting
that MK may contribute to mucosal repair [36]. Thus, the inﬂammatory cytokines TNF-α and IL-1β may
facilitate wound repair by upregulating MK. However, the question whether MK is beneﬁcial for mucosa
repair or rather promotes inﬂammation requires further investigation.
4.5. Central Nervous System
MK has also been investigated in a chronic inﬂammatory disease affecting the central nervous system,
namely, multiple sclerosis (MS). In Europe around 500,000 people suffer from MS [74]. MS is a chronic
autoimmune disease that is characterized by demyelination of axons of the central nervous system
caused by autoreactive T-cells and demyelinating antibodies. To study MS, experimental autoimmune
encephalomyelitis (EAE) has been used as a widely accepted animal model where demyelination is
induced by injection of myelin-oligodendrocyte-glycoprotein leading to TH1a n dT H17 cell-mediated
inﬂammation [75, 76]. After induction of EAE in rats, increased MK mRNA expression in the spinal
cord correlated with the severity of clinical symptoms such as limb and tail weakness. Recovery of
clinical symptoms led to decreased MK expression in the spinal cord again [37]. EAE induction of WT
mice caused severe clinical symptoms 18 days after onset of the experiment. MK-deﬁcient mice also
developed clinical signs of encephalomyelitis. However, clinical scores were signiﬁcantly lower than in WT
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control animals. Administration of recombinant MK with a subcutaneously implanted microosmotic pump
deteriorated clinical scores [13]. Histological analysis of the spinal cord revealed decreased inﬁltration of
inﬂammatory cells in the spinal cord in MK-deﬁcient mice compared to WT control animals, whereas MK
application restored this effect showing positive correlation of clinical ﬁndings and histological analysis
[13]. This indicates that MK was important for induction and development of EAE. CD4+ and CD8+ T cell
populations were similar in peripheral lymph nodes of WT and MK-deﬁcient mice and, therefore, did not
explainreducedclinicalandhistopathologicalseverityinMK-deﬁcientmice.AfteronsetofEAE,expansion
of CD4+/CD25+ regulatory T-cells (Treg), which have the ability to suppress autoreactive TH1a n dT H17
cells, was signiﬁcantly increased in peripheral lymph nodes in the absence of MK [13, 77]. Accordingly,
administration of MK critically suppressed Treg expansion in a dose-dependent manner in vitro and in vivo.
When Treg were targeted with a CD25 blocking antibody in MK-deﬁcient mice, suppression of EAE was
abolished [13]. These ﬁndings indicate that an increased number of Treg were recruited to peripheral lymph
nodes when MK was absent after induction of EAE leading to attenuated clinical and histopathological
symptoms in this model [13]. Furthermore, it was shown that CD4+ T-cells from MK-deﬁcient mice after
induction of EAE expressed lower amounts of IFN-γ and IL-17, cytokines which are critically involved in
the pathogenesis of several autoimmune diseases [78]. It could also be shown that targeting MK by RNA
aptamers signiﬁcantly increased Treg expansion and improved clinical signs after induction of EAE in WT
mice [13]. Taken together, MK expression has been shown to be enhanced during induction and progression
of EAE which correlated positively with clinical scores and histopathological signs of inﬂammation of the
myelin sheath. MK suppressed expansion of Treg and enhanced autoreactive injury of the myelin sheath.
Targeting MK led to increased Treg expansion and subsequently suppressed autoreactive TH1a n dT H17 cell
populations in this model which are critically involved in the pathogenesis of autoimmune diseases.
5. OUTLOOK AND PERSPECTIVES
Being diagnosed with autoimmune diseases such as multiple sclerosis, ulcerative colitis, Crohn’s disease,
or rheumatoid arthritis critically affects the patients’ quality of life [79, 80]. Especially the early onset and
gradual progression of disease over a long period of time makes therapy and treatment for clinicians and
patients very challenging [81]. Immunosuppressive drugs, corticosteroids, cytostatics, and biological drugs
speciﬁcally targeting proteins involved in the inﬂammatory response can effectively suppress autoimmune
responses. However, severe side effects, for example, increased risk of infection, cancer, and other
autoimmunediseases,maketreatmentoptionsunsatisfying[81].Similartoautoimmunedisorders,anumber
of additional widespread diseases including atherosclerosis are characterized by chronic inﬂammatory
processes [70]. Different studies have shown that MK plays a role in inﬂammation by induction of leukocyte
inﬁltration and chemokine expression as well as by suppression of Treg expansion. As MK shows highly
restrictive expression patterns in healthy tissues of the adult organism, targeting MK may represent a
promising new approach for treatment of chronic inﬂammation including autoimmune diseases.
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